ME 23ANDME HLDG CO

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

“Seat 16” program allows audiences to share the critically acclaimed film with teens across the country

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film and the film’s groundbreaking  program. Seat16 allows anyone to gift $16 or more to purchase an ORIGIN movie ticket for a young person who might not otherwise be able to purchase a ticket to the film. For 23 days, 23andMe will donate 100 seats daily to support the program.

ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN.

Written, directed, and produced by Academy Award nominee Ava DuVernay, ORIGIN explores the mystery of history, the wonders of romance, and a fight for our future. While investigating the global phenomenon of caste and its dark influence on society, a journalist faces unfathomable personal loss and uncovers the beauty of human resilience. With an expansive cast that includes Academy Award nominee Aunjanue Ellis-Taylor, Jon Bernthal, and Niecy Nash-Betts, the film was inspired by Pulitzer Prize-winning journalist Isabel Wilkerson's novel Caste: The Origin of Our Discontents.

“It’s a scientific fact we are all 99.5 percent genetically identical. We are more alike than we are different and sometimes people forget humans have created hierarchies and caste systems. As a brand we focus on the knowledge that we are all connected, equally, through our DNA,” said Tracy Keim, Chief Brand Officer at 23andMe. “Supporting Ava DuVernay, ARRAY and the ORIGIN team by purchasing tickets for young adults through their Seat 16 program, encourages a new generation to have the opportunity to be educated through the film’s storytelling about our connection, not our differences.”

View the film's trailer . Through her foundation, 23andMe co-founder and CEO Anne Wojcicki helped fund the film along with several other non-profits.

About 23andMe

23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit .

Contacts

Media Contact: 



EN
31/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on 23ANDME HLDG CO

 PRESS RELEASE

TTAM Research Institute, A Nonprofit Public Benefit Corporation, Compl...

TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co. (together with its debtor subsidiaries, the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, under Section 363 of the U.S. Bankruptcy C...

 PRESS RELEASE

23andMe Receives Court Approval for Sale to TTAM Research Institute, a...

23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a genetics-led consumer healthcare company, today announced that it has received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court") for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andM...

Pierre FerraguÊ
  • Pierre FerraguÊ

The Tech Infrastructure Quarterly Bible 1Q25

We publish today our comprehensive quarterly bible: 237 pages of detailed analyses on what happened in the last 3 months, and how we interpret it, in light of our current convictions. The first section acts as a PM summary, outlining our key findings, and latest thoughts on the semi cycle, in 6 slides.

 PRESS RELEASE

23andMe Reaches Agreement for Sale of Business to TTAM Research Instit...

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process TTAM Commits to Comply with Company’s Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics ...

 PRESS RELEASE

23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregis...

23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “SEC”) on or about June 6, 2025, which will remove its securities from listing and registration on Nasdaq. Nasdaq previously suspended the trading of 23andMe’s Class A common stock, $0.0001 par value per share (the “Common...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch